Artículo original 15 de agosto de 2026

PET/TC con 13N-amonio y 18F-FDG en el diagnóstico y monitoreo del tratamiento de la sarcoidosis cardíaca

Referenciar Imprimir

Referencias

  1. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.
  2. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease. Eur Heart J. 2007;28:3076–3093.
  3. Campisi R, Merani MF, Marina MI. BMIPP SPECT in cardiac sarcoidosis: A marker of risk? J Nucl Cardiol 2021;28(3):930–5.
  4. Diagnostic standard and guidelines for sarcoidosis. Japanese J Sarcoidosis Granulomatous Disord. 2007;27:89-102.
  5. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–1323.
  6. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, Kazemian P, Kwong RY, Tokuda M, Skali H, Padera R, Hainer J, Stevenson WG, Dorbala S, Di Carli MF. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–336. doi: 10.1016/j.jacc.2013.09.022.
  7. Bravo PE, Raghu G, Rosenthal DG, et al. Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging. Int J Cardiol 2017; 241:457.
  8. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003; 44:1030–6.
  9. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241.
  10. Campisi R, Merani MF, Rodriguez MI. Current Cardiology Reports, 2022, 24(12):1873-1882. https://doi.org/10.1007/s11886-022-01803-4
  11. Chareonthaitawee P, Beanlands RS, Chen W, et al. Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/TC in cardiac sarcoid detection and therapy monitoring. J Nucl Cardiol 2017; 24:1741.
  12. Wiefels C, Boczar K, Birnie D, et al. Quantification of metabolic activity in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2024. https://doi.org/10.1016/j.nuclcard.2024.102088.
  13. Ahmadian A, Brogran A, Berman J, Sverdlow AL, Mercier G, Mazzini M, et al. Quantitative interpretation of FDG PET/TC with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol. 2014;21:925–39.
  14. Vita T, Okada DR, Veillet-Chowdhury M, et al. Complementary Value of Cardiac Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Assessment of Cardiac Sarcoidosis. Circ Cardiovasc Imaging 2018; 11:e007030.
  15. Slart RHJA, Glaudemans AWJM, Lancellotti P, Hyafil F, Blankstein R, Schwartz RG, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018;25:298–319.
  16. Bravo P and Taqueti V. Cardiac MRI vs. PET for the evaluation of cardiac sarcoidosis: Consider MRI first. J Am Coll of Cardiol April 10, 2017. Expert analysis.
  17. Ahluwalia et al. A new era of imaging for diagnosis and management of cardiac sarcoidosis: Hybrid cardiac magnetic resonance imaging and positron emission tomography. J Nucl Cardiol 2019 Dec;26(6):1996-2004.
  18. Tilkemeier PL, Bourque J, Doukky R et al. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. J Nucl Cardiol. 2017 Sep 15.
  19. Bokhari S, Lin JC, Julien HM. FDG is a superior tool in the diagnosis and management of cardiac sarcoidosis. J Am Coll of Cardiol April 10, 2017. Expert analysis.
  20. Bois JP, Muser D, Chareonthaitawee P. PET/TC evaluation of cardiac sarcoidosis. PET Clin 2019;14(2): 223-32.
  21. Treglia G, Taralli S, Mattoli MV, Giordano A. Utility of whole-body Fluorine-18-fluorodeoxyglucose positron emission tomography in patients with sarcoidosis. In: Medical Imaging: Procedures, Techniques and Applications, 2012. p.39-50.
  22. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011; 97:2078.